• By Concept
  • By Last Name
  • By Full Text

Sunderland, Trey

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.



CHOLINERGIC TREATMENT OF MEMORY DEFICITS IN THE AGED

Davis, Kenneth L

1 April 1980 - 31 March 1994
NATIONAL INSTITUTE ON AGING
Total Funding: $ 4,180,669

FY 1989
2P01AG002219-09A1
$ 720,245
FY 1987
5P01AG002219-08
$ 535,569
FY 1988
3P01AG002219-08S1
$ 570,802
FY 1986
3P01AG002219-07S1
$ 0
FY 1986
5P01AG002219-07
$ 478,707
FY 1986
3P01AG002219-06S1
$ 0
FY 1985
5P01AG002219-06
$ 444,434
FY 1984
5P01AG002219-05
$ 411,684
FY 1983
2P01AG002219-04
$ 374,491
FY 1982
5P01AG002219-03
$ 220,672
FY 1981
5P01AG002219-02
$ 209,564
FY 1980
1P01AG002219-01
$ 214,501
 
 
$ 4,180,669
Abstract

Neurochemical and pharmacological studies establish a rationale for clinical trials of drugs that increase central cholinergic activity in patients with a diagnosis of Alzheimer's disease, and in normal elderly people with an age-related loss in memory functioning. The major goal of the project is to test potential cholinomimetic compounds in patients with Alzheimer's disease, normal elderly people with an age-related memory loss and in normal young subjects, to determine the ability of these drugs to enhance memory functioning. Various cholinergic agents with different mechanisms of action will be tested and compared in the same patients to determine their relative abilities to imprve the ability of patients and subjects to learn new information. These drugs include, precursors to acetylcholine, acetylcholinesterase inhibitors and muscarinic receptor agonists. In all instances broad dose ranging studies are a prerequisite to subsequent studies. As these sudies are being conducted, an attempt will be made to determine if the cholinergic deficit that exists in Alzheimer's disease, and exists to a lesser extent in normal elderly people, can be detected in vivo by measurements of cerebrospinal fluid or neuroendocrine parameters.

175 Resulting Publications

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.

Related Grants

Related Publications